natgillin/translations-raw huggingface dataset:
Tabel over bivirkninger ved behandling af brystkræft med docetaxel 100 mg/m² i kombination med trastuzumab: 
Tabulated list of adverse reactions in breast cancer for docetaxel 100 mg/m2 in combination with trastuzumab
Hver karton indeholder et hætteglas med 4 ml koncentrat Hver karton indeholder et hætteglas med 8 ml koncentrat 
Each box contains one vial of 8 ml concentrate.
Docetaxel Accord 80 mg/4 ml leveres i et 5 ml klart glashætteglas med fluorotec plus gummilukning og aluminiumforsegling og en rød afrivningshætte. 
Docetaxel Accord 80 mg/4 ml is supplied in a 5 ml clear glass vial with fluorotec plus rubber stopper and aluminium seal and a red flip-off cap.
Asteni (alvorlig: 12,4 %); Væskeretention (alvorlig: Smerter 
Asthenia (severe: 12.4%); Fluid retention (severe: 0.8%); Pain
Docetaxel Accord 80 mg/4 ml koncentrat til infusionsvæske, opløsning docetaxel 
NAME OF THE MEDICINAL PRODUCT Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion docetaxel
Tabel over bivirkninger ved behandling af brystkræft med docetaxel 75 mg/m² i kombination med doxorubicin: 
Tabulated list of adverse reactions in breast cancer for docetaxel 75 mg/m2 in combination with doxorubicin
• Induktions kemoterapi efterfulgt af kemo-stråleterapi (TAX 324) Til den indledende behandling af patienter med lokalt fremskreden pladecellecarcinom i hoved og hals (SCCHN) (ikke muligt af resektere, lav sandsynlighed for kirurgisk helbredelse samt med bevarelse af organer som mål), er den anbefalede dosis docetaxel 75 mg/m2 som en 1-times intravenøs infusion på dag 1, efterfulgt af cisplatin 100 mg/m2 administreret som en 30 minutter til 
For the induction treatment of patients with locally advanced (technically unresectable, low probability of surgical cure, and aiming at organ preservation) squamous cell carcinoma of the head and neck (SCCHN), the recommended dose of docetaxel is 75 mg/m2 as a 1 hour intravenous infusion on day 1, followed by cisplatin 100 mg/m2 administered as a 30-minute to 3-hour infusion, followed by 5-fluorouracil 1000 mg/m2/day as a continuous infusion from day 1 to day 4.
Docetaxel Accord monoterapi er indiceret til behandling af patienter med lokalt fremskreden eller metastatisk brystkræft efter behandlingssvigt af kemoterapi. 
Docetaxel Accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.
Tabel over bivirkninger ved behandling af hoved- og halskræft med docetaxel 75 mg/m² i kombination med cisplatin og 5-fluoruracil: 
Tabulated list of adverse reactions in head and neck cancer for docetaxel 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Docetaxel i kombination med trastuzumab 
Docetaxel in combination with trastuzumab
Stomatitis (G3/4: 1,7 %); Opkastning (G3/4: 0,8 %); Diarré (G3/4: 1,7 %) 
Stomatitis (G3/4: 1.7%); Vomiting (G3/4: 0.8%);
Kløende udslæt (G3/4: 0,7 %); Neglesygdomme (G3/4: 0,7 %); Hudafskalning (G3/4: 0 %) 
Rash pruritus (G3/4: 0.7%); Nail disorders (G3/4: 0.7%); Skin exfoliation (G3/4: 0%)
Docetaxel Accord 160 mg/8 ml koncentrat til infusionsvæske, opløsning Hvert hætteglas med koncentrat indeholder 2 ml vandfri ætanol (1,58 mg). 
Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion Each vial of concentrate contains 2 ml of ethanol anhydrous (1.58 g).
Neglesygdomme (G3/4: 2 %) 
Stomatitis (G3/4: 2%)
Efter stratificering i henhold til antallet af positive lymfeknuder (1-3, 4+), blev 1491 patienter randomiseret til enten at få enten docetaxel 75 mg/m2 administreret en time efter doxorubicin 50 mg/m2 og cyclophosphamid 500 mg/m2 (TAC-arm), eller doxorubicin 50 mg/m2, fulgt af fluoruracil 500 mg/ m2 og cyclophosphamid 500 mg/m2 (FAC-arm). 
patients were randomised to receive either docetaxel 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (TAC arm), or doxorubicin 50 mg/m2 followed by fluorouracil 500 mg/m2 and cyclosphosphamide 500 mg/m2 (FAC arm).
Tabel over bivirkninger ved behandling af gastrisk adenokarcinom med docetaxel 75 mg/m² ikombination med cisplatin og 5-fluoruracil: 
Tabulated list of adverse reactions in gastric adenocarcinoma cancer for docetaxel 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Mave-tarmkanalen Stomatitis (G3/4: Diarré (G3/4: 4 %); 
Stomatitis (G3/4: 5.3%); Diarrhoea (G3/4: 4%);
Myalgi (G3/4: 0,7 %); Artralgi (G3/4: 0,2 %) 
Myalgia (G3/4: 0.7%); Arthralgia (G3/4:
Hjælpestof(fer), som behandleren skal være opmærksom på Docetaxel Accord 20 mg/1 ml koncentrat til infusionsvæske, opløsning Hvert hætteglas med koncentrat indeholder 0,5 ml vandfri ætanol (395 mg). 
Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion Each vial of concentrate contains 0.5 ml of ethanol anhydrous (395 mg).
Hud og subkutane væv Alopeci; Hudlidelser (G3/4: 
Alopecia ( persisting: Skin disorder (G3/4:
Første episode: Reducer docetaxel- og 5-FU-dosis med 20 % Anden episode: Afbryd behandlingen 
Diarrhoea grade 4 First episode: reduce docetaxel and 5-FU doses by 20%.
Mave-tarmkanalen Kvalme (G3/4: 9,6 %); Opkastning (G3/4: 
Nausea (G3/4: 9.6%); Vomiting (G3/4:
Letargi 
Arthralgia
ANVENDELSESMÅDE OG ADMINISTRATIONSVEJ(E) BEMÆRK: Klar til tilsætning til infusionsvæske. 
CAUTION: Ready to add to infusion solution
Væskeretention G3/4: Ødemer (G3/4: 1,2%) 
Fluid retention (severe: Fever (G3/4: 1.2%)
ENDEPUNKT 
Endpoint
Konstipation (G3/4: 
Constipation (G3/4:
Patienter i docetaxel-armen fik docetaxel (T) 75 mg/m2 ved intravenøs infusion på dag 1, efterfulgt af cisplatin (P) 100 mg/m2 administreret som en 30 minutter til 
Patients on the docetaxel arm received docetaxel (T) 75 mg/m² by intravenous infusion on day 1 followed by cisplatin (P) 100 mg/m² administered as a 30-minute to three-hour intravenous infusion, followed by the continuous intravenous infusion of 5-fluorouracil (F) 1000 mg/m²/day from day 1 to day 4.
Docetaxel Accord 20 mg/1 ml indeholder 50 % vol. vandfri ætanol (alkohol), dvs. op til 395 mg vandfri ætanol pr. hætteglas, svarende til 10 ml øl eller 4 ml vin. 
50 vol % ethanol anhydrous (alcohol), i.e. up to 395 mg ethanol anhydrous per vial, equivalent to 10 ml of beer or 4 ml wine.
Tabel over bivirkninger ved behandling af brystkræft med docetaxel 100 mg/m² enkeltstof: 
Tabulated list of adverse reactions in breast cancer for docetaxel 100 mg/m2 single agent
Trombocytopeni; (G3/4: 0,6 %); Febril neutropeni 
Thrombocytopenia (G3/4: Febrile neutropenia
I studiet GEICAM 9805 blev det observeret, at perifert ødem, som forekom i løbet af behandlingsperiden, fortsatte ind i opfølgningsperioden hos 4 patienter (0,8 %) i TAC-armen og hos 2 patienter (0,4 %) i FAC-armen. 
In study GEICAM 9805 peripheral oedema that started during the treatment period persisted into the follow-up period in 4 patients (0.8%) in TAC arm and in 2 patients (0.4%) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), no patients (0%) in TAC arm had peripheral oedema and it was observed to be ongoing in 1 patient (0.2%) in FAC arm.
Dysgeusi/parosmi Perifer sensorisk neuropati (G3/4: 0,6 %) 
Peripheral sensory neuropathy (G3/4: 0.6%)
Forhøjet lakrimation (G3/4: 0 %) 
Weight increased (G3/4: 0%);
Dette regime blev administreret hver 3. uge i 4 
This regimen is administered every
Feber (G3/4: 1,2 %) 
(G3/4: 1.2%)
Diarré (G3/4: 19,7 %); 
Diarrhoea (G3/4: 1.7%)
4.4 og pkt. 
3 weeks for 4 cycles.
95 %CI P = Hazard ratio* 
95% CI p-value*
Opbevar dette lægemiddel utilgængeligt for børn. 
How to store Docetaxel Accord Keep this medicine out of the sight and reach of children.
Svimmelhed (G3/4: 
Vomiting (G3/4:
Arytmi (G3/4: 0,7 %) Hjertesvigt 
Arrhythmia (G3/4: 0.7%)
I studiet GEICAM9805 fortsatte alopeci, som forekom i løbet af behandlingsperioden, og blev fortsat observeret hos 49 patienter (9,2%) i TAC-armen og hos 35 patienter (6,7%) i FAC-armen. 
In GEICAM 9805 study alopecia that started during the treatment period and persisted into the follow-up period was observed to be ongoing in 49 patients (9.2 %) in TAC arm and 35 patients (6.7 %) in FAC arm. Alopecia related to study drug started or worsened during the follow-up period in 42 patients (7.9 %) in TAC arm and 30 patients (5.8 %) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), alopecia was observed to be ongoing in 3 patients (0.6%) in TAC arm, and in 1 patient (0.2%) in FAC arm.
Dato for første markedsføringstilladelse: 12. juni 2009 
Date of first authorisation:12 June 2009
Den absolutte biotilgængelighed for en tablet er omkring 77%. 
The absolute bioavailability from the tablet was found to be about 77 %.
De hyppigst rapporterede bivirkninger er diaré og hovedpine, som begge forekommer hos ca. 1 % af patienterne. 
The most commonly reported adverse reactions are diarrhoea and headache, both occuring in approximately 1% of patients.
Absorptionen af atazanavir er pH-afhængig. 
The absorption of atazanavir is pH-dependent.
Meget almindelig (≥1/10); almindelig (≥1/100 til <1/10); ikke almindelig (≥1/1.000 til < 1/100); sjælden (≥1/10.000 til <1/1.000); meget sjælden (<1/10.000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data). 
Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
GORDdiagnosen i disse studier er baseret på endoskopisk vurdering, med undtagelse af et enkelt studie, hvor inkluderingen af patienter alene var baseret på symptomatologi. 
GORD diagnosis in these studies was based on endoscopic assessment, with the exception of one study in which the inclusion of the patients was based on symptomatology alone.
Den lille stigning i AUC og Cmax hos ældre forsøgspersoner i forhold til yngre har ingen klinisk relevans. 
The slight increase in AUC and Cmax in elderly volunteers compared with younger subjects was not clinically relevant.
Det forventes, at der i gennemsnit er 5 % af patienterne, som oplever bivirkninger. 
Approximately 5% of patients can be expected to experience adverse reactions .
• de er under kontinuerlig symptomatisk behandling af fordøjelsesbesvær eller halsbrand i mere end 4 uger. 
• They are on continuous symptomatic treatment of indigestion or heartburn for 4 or more weeks.
PANTECTA Control 20 mg enterotabletter bør ikke tygges eller knuses, men skal sluges hele med væske før et måltid. 
PANTECTA Control 20 mg gastro-resistant tablets should not be chewed or crushed, and should be swallowed whole with liquid before a meal.
PANTECTA Control påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner. 
PANTECTA Control has no or negligible influence on the ability to drive and use machines.
Patienter bør ikke tage andre protonpumpehæmmere eller H2-antagonister samtidigt . 
Patients should not take another proton pump inhibitor or H2 antagonist concomitantly.
Det er ukendt, om pantoprazol udskilles i humanmælk . 
It is unknown whether pantoprazole is excreted in human breast milk.
Tag ikke PANTECTA Control: - hvis du er allergisk over for pantoprazol eller et af de øvrige indholdsstoffer (angivet i afsnit 6 
Do not take PANTECTA Control: - if you are allergic to pantoprazole or to any of the other ingredients of this medicine (listed in section 6).
Specielt patienter over 55 år, som dagligt tager ikkereceptpligtige lægemidler mod fordøjelsesbesvær og halsbrand, bør informere deres apotek eller læge. 
Especially, patients over 55 years taking any non-prescription indigestion or heartburn remedy on a daily basis should inform their pharmacist or doctor.
PANTECTA Control må ikke bruges af børn og unge under 18 år pga. manglende dokumentation for sikkerhed i denne aldersgruppe. 
PANTECTA Control should not be used by children and adolescents under 18 years of age due to a lack of safety information in this younger age group..
PANTECTA Control bør ikke anvendes til børn og unge under 18 år på grund af utilstrækkelige data vedrørende sikkerhed og virkning. 
PANTECTA Control is not recommended for use in children and adolescents below 18 years of age due to insufficient data on safety and efficacy.
I dyrestudier (rotter) var den observerede NOAEL (intet bivirkningsniveau observeret) 5 mg/kg for embryotoksicitet. 
In animal studies (rats) 5 mg/kg was the observed NOAEL (No Observed Adverse Effect Level) for embryotoxicity.
Stop med at tage PANTECTA Control, når du er symptomfri. 
Stop taking PANTECTA Control when you are completely symptom-free.
- Øvrige indholdsstoffer : 
- The other ingredients are:
Forhøjede leverenzymer (transaminaser, γ-GT) 
Liver enzymes increased (transaminases, γ-GT)
Hvis du har taget for meget PANTECTA Control Fortæl det til lægen eller apoteket hvis du har taget mere end den anbefalede dosis. 
If you take more PANTECTA Control than you should Tell your doctor or pharmacist if you have taken more than the recommended dose.
PANTECTA Control findes i aluminim/aluminium-blister med eller uden kartonforstærkning. 
PANTECTA Control is available in Alu/Alu blisters with or without cardboard reinforcement.
Tag ikke PANTECTA Control samtidigt med anden medicin, som begrænser mængden af syre i din mave, så som andre syrepumpehæmmere (omeprazol, lansoprazol eller rabeprazol) eller en H2antagonist (f.eks. ranitidin, famotidin). 
Do not take PANTECTA Control with other medicines which limit the amount of acid produced in your stomach, such as another proton pump inhibitor (omeprazole, lansoprazole or rabeprazole) or an H2 antagonist (e.g. ranitidine, famotidine).
Efter 14 og 28 dage oplevede henholdsvis 62,9 % til 88,6 % og 68,1 % til 92,3 % af patienterne fuldstændig lindring af halsbranden. 
After 14 and 28 days, complete heartburn relief was experienced in 62.9% to 88.6% and 68.1% to 92.3% of the patients, respectively.
Det er vist, at samtidig anvendelse af atazanavir 300 mg/ ritonavir 100 mg og omeprazol (40 mg én gang daglig) eller atazanavir 400 mg og lanzoprazol (60 mg givet som enkeltdosis) hos raske forsøgspersoner har medført en betydelig reduktion i atazanavirs biotilgængelighed. 
It has been shown that co-administration of atazanavir 300 mg/ritonavir 100 mg with omeprazole (40 mg once daily) or atazanavir 400 mg with lansoprazole (60 mg single dose) to healthy volunteers resulted in a substantial reduction in the bioavailability of atazanavir.
PANTECTA Control indeholder det aktive stof pantoprazol, som blokerer den ”pumpe”, der producerer mavesyre. 
PANTECTA Control contains the active substance pantoprazole, which blocks the ‘pump' that produces stomach acid.
Du må ikke tage PANTECTA Control, hvis du tager atazanavir. 
You must not use PANTECTA Control if you are taking atazanavir.
I disse studier var procentdelen af de patienter, som opnåede fuldstændig lindring af halsbranden efter 7 dage, mellem 54,0% og 80,6 % i gruppen som blev behandlet med pantoprazol. 
In these studies, the percentage of patients experiencing complete relief from heartburn after 7 days was between 54.0% and 80.6% in the pantoprazole group.
Se 'tag ikke PANTECTA Control'. 
See ‘Do not take PANTECTA Control'.
- Methotrexat (bruges til behandling af reumatoid artrit, psoriasis og cancer) - hvis du tager methotrexat, kan din læge midlertidigt stoppe din behandling med PANTECTA Control, da PANTECTA Control kan forøge niveauet af methotrexat i blodet. 
You may need further blood tests - methotrexate (used to treat rheumatoid arthritis, psoriasis, and cancer) - if you are taking methotrexate your doctor may temporarily stop your PANTECTA Control treatment because pantoprazole can increase levels of methotrexate in the blood.
Derfor bør pantoprazol ikke gives sammen med atazanavir (se pkt. 
Therefore, pantoprazole must not be co-administered with atazanavir (see section 4.3).
PANTECTA Control kan reducere absorptionen af aktive stoffer, hvis biotilgængelighed er pHafhængig (fx. ketoconazol). 
PANTECTA Control may reduce the absorption of active substances whose bioavailability is dependent on the gastric pH (e.g. ketoconazole).
Dyrestudier har vist, at pantoprazol udskilles i brystmælk. 
Animal studies have shown excretion of pantoprazole in breast milk.
Farmakoterapeutisk klassifikation: Protonpumpehæmmere, ATC-kode: A02BC02 
Pharmacotherapeutic group: : Drugs for acid related disorders,Proton pump inhibitors, ATC code: A02BC02
Hyponatræmi, hypomagnesæmi 
Hyponatraemia, Hypomagnesaemia
Derfor bør patienter, der er i behandling med kumarinantikoagulantia (f.eks. phenprocoumon eller warfarin), have foretaget ekstra analyser af prothrombintid/INR ved behandlingsstart og -ophør samt ved uregelmæssig brug af pantoprazol. 
Therefore, in patients treated with coumarin anticoagulants (e.g. phenprocoumon or warfarin), monitoring of prothrombin time/INR is recommended after initiation, termination or during irregular use of pantoprazole.
Du kan opleve lindring af dine symptomer på sure opstød og halsbrand efter kun en dags behandling med PANTECTA Control, men denne medicin har ikke til hensigt at give øjeblikkelig lindring. 
You may experience relief from your acid reflux and heartburn symptoms after just one day of treatment with PANTECTA Control, but this medicine is not meant to bring immediate relief.
Du må gerne tage PANTECTA Control samtidig med syreneutraliserende medicin (f.eks. magaldrat, alginsyre, natriumbicarbonat, aluminiumhydroxid, magnesiumcarbonat eller kombinationer heraf), hvis det er nødvendigt. 
However, you may take PANTECTA Control with antacids (e.g. magaldrate, alginic acid, sodium bicarbonate, aluminium hydroxide, magnesium carbonate, or combinations thereof), if needed.
PANTECTA Control bør ikke anvendes under graviditet. 
Pantoprazole should not be used during pregnancy.
- hvis du tager medicin, som indeholder atazanavir (til behandling af HIV-infektion). 
- if you are taking a medicine containing atazanavir (for the treatment of HIV-infection) See
Tag ikke PANTECTA Control-tabletter i mere end 4 uger uden at kontakte lægen. 
Do not take PANTECTA Control tablets for more than 4 weeks without consulting your doctor.
Hallucinationer, forvirring (specielt hos patienter som i forvejen har haft disse symptomer); nedsat natrium;og magnesium i blodet. 
- Frequency not known: hallucination, confusion (especially in patients with a history of these symptoms); decreased level of sodium in blood; decreased level of magnesium in blood.
Du kan finde yderligere information om PANTECTA Control på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu/. 
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Fortæl det straks til lægen før eller efter du har taget medicinen, hvis du oplever nogle af følgende symptomer, som kan være et tegn på en anden, mere alvorlig, sygdom: - uventet vægttab (som ikke er relateret til diæt eller et motionsprogram) - opkastning, især ved gentagelse - blodigt opkast, dette kan ses som mørkt kaffegrums i dit opkast - du opdager blodig afføring, som kan være sort eller tjærefarvet - synkebesvær eller smerte i forbindelse med synkning - du ser bleg ud eller føler dig sløj (blodmangel) - brystsmerter - mavesmerter - kraftig og/eller vedvarende diaré, da dette lægemiddel er forbundet med en let øget risiko for infektiøs diaré 
Tell your doctor immediately, before or after taking this medicine, if you notice any of the following symptoms, which could be a sign of another, more serious, disease: - an unintentional loss of weight (not related to a diet or an exercise programme) - vomiting, particularly if repeated - vomiting blood; this may appear as dark coffee grounds in your vomit - you notice blood in your stools; which may be black or tarry in appearance - difficulty in swallowing or pain when swallowing - you look pale and feel weak (anaemia) - chest pain - stomach pain - severe and/or persistent diarrhoea, because this medicine has been associated with a small increase in infectious diarrhoea.
Overtræk: hypromellose, povidon K25, titandioxid (E 171), gul jernoxid (E 172), propylenglycol, methacrylsyre-ethylacrylat copolymer (1:1), natriumlaurilsulfat, polysorbat 80, triethylcitrat. 
Coating: hypromellose, povidone, titanium dioxide (E171), yellow iron oxide (E172), propylene glycol, methacrylic acid-ethyl acrylate copolymer, sodium lauril sulfate, polysorbate 80, triethyl citrate.
Det skal du vide, før du begynder at tage PANTECTA Control 
What you need to know before you take PANTECTA Control
Blæk til prægning: Shellac; rød, sort og gul jernoxid (E 172); koncentreret ammoniakopløsning. 
Printing ink: shellac, red, black and yellow iron oxide (E172) and ammonia solution, concentrated.
Povidon K25 
Hypromellose Povidone K25
Hvis du har glemt at tage PANTECTA Control Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. 
Do not take a double dose to make up for the forgotten dose.
ketoconazol (bruges ved svampeinfektion) - warfarin og phenprocoumon (medicin som virker blodfortyndende og forebygger blodpropper). 
- warfarin and phenprocoumon (used to thin blood and prevent clots).
- Meget sjældne bivirkninger (kan påvirke færre end 1 ud af 10.000 patienter): Desorientering; nedsat antal blodplader i blodet, hvilket kan medføre at du lettere bløder eller får blå mærker; nedsat antal hvide blodlegemer, hvilket kan øge tendensen til betændelse; unormal reduktion af antallet af hvide og røde blodlegemer samt blodplader (i blodprøver). 
- Very rare side effects (may affect up to 1 in 10,000 people): disorientation; reduction in the number of blood platelets, which may cause you to bleed or bruise more than normal; reduction in the number of white blood cells, which may lead to more frequent infections; coexisting abnormal reduction in the number of red and white blood cells, as well as platelets (seen in blood tests).
Blod og lymfesystem 
Blood and lymphatic system disorders Immune system disorders
Kerne: Natriumcarbonat, vandfrit; mannitol (E 421), crospovidon, povidon K90, calciumstearat. 
Core: sodium carbonate (anhydrous), mannitol, crospovidone, povidone K90, calcium stearate.
- atazanavir (bruges til behandling af HIV-infektion). 
- ketoconazole (used for fungal infections).
Enterotabletterne er gule, ovale, bikonvekse filmovertrukne tabletter præget med ”P20” på den ene side. 
What PANTECTA Control looks like and contents of the pack The gastro-resistant tablets are yellow, oval, biconvex film-coated tablets imprinted with “P20” on one side.
PANTECTA Control bruges til korttidsbehandling af reflukssymptomer (f.eks. halsbrand og sure opstød) hos voksne. 
PANTECTA Control is used for the short-term treatment of reflux symptoms (for example heartburn, acid regurgitation) in adults.
Sådan skal du tage PANTECTA Control 
How to take PANTECTA Control
- Ikke almindelige bivirkninger ( kan påvirke mellem 1 og 100 personer): Hovedpine; svimmelhed; diaré; kvalme, opkastning; oppustethed og luftafgang fra tarmen; forstoppelse; mundtørhed; smerter og ubehag i maven; hududslæt og eksem; kløe; svaghedsfornemmelse, udmattet eller generelt utilpas; søvnforstyrrelser; forøgede leverenzymtal ved blodprøve. 
- Uncommon side effects(may affect up to 1 in 100 people): headache; dizziness; diarrhoea; feeling sick, vomiting; bloating and flatulence (wind); constipation; dry mouth; bellyache and discomfort; skin rash or hives; itching; feeling weak, exhausted or generally unwell; sleep disorders; increase in liver enzymes in a blood test.
Chokolade, pebermynte, spearmint, fed og friturestegt mad, syreholdig mad, krydret mad, 
spearmint, fatty and fried food, acidic food, spicy food, citrus fruits and fruit juices, tomatoes.
PANTECTA Control er indiceret til korttidsbehandling af reflukssymptomer (fx halsbrand, syreregurgitation) hos voksne. 
PANTECTA Control is indicated for short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.